Most children diagnosed with leukemia today are cured. The overall five-year survival rate for childhood leukemia is 86.7%, and that number has been climbing steadily, reaching above 90% in recent years for the most common subtype. The word “cure” carries a specific meaning in oncology, and the outlook varies depending on the type of leukemia, how it responds to treatment, and certain genetic features of the cancer itself.
Survival Rates by Type
About 80% of childhood leukemia cases are acute lymphoblastic leukemia (ALL), which is the more treatable form. Five-year survival for ALL now exceeds 90% at many treatment centers. The trend line has been moving in the right direction for over a decade: SEER registry data shows survival climbing from roughly 85% in 2008 to over 90% by 2018.
Acute myeloid leukemia (AML) is less common and harder to treat. The cure rate for childhood AML in developed countries is around 60%, with overall survival in the 60 to 70% range. AML requires more intensive chemotherapy and sometimes a bone marrow transplant, and the treatment itself carries greater risks.
When Doctors Use the Word “Cure”
In pediatric leukemia, “cure” doesn’t just mean the cancer is gone right now. It means the cancer is gone and almost certainly not coming back. Researchers at St. Jude Children’s Research Hospital have proposed that a child who remains in complete remission for at least four years after finishing all treatment can practically be considered cured, because relapse after that point is exceedingly rare. An older, more conservative benchmark defined cure as 10 or more years of event-free survival.
For children with certain genetic subtypes, the picture becomes clear even sooner. Kids whose leukemia carries specific chromosomal rearrangements (like the Philadelphia chromosome translocation) have not been observed to relapse beyond two years after completing therapy, meaning they may be declared cured earlier than other patients.
What Treatment Looks Like
Treatment for childhood ALL typically lasts two to three years and moves through distinct phases. The first phase, called induction, lasts about four weeks and aims to eliminate detectable leukemia cells from the blood and bone marrow. Most children achieve complete remission during this phase.
After induction comes a series of intensification rounds designed to destroy any remaining cancer cells hiding in the body. This is followed by a long maintenance phase, often lasting a year or more, involving daily and weekly oral medications along with periodic stronger treatments. The entire process is almost entirely chemotherapy-based for standard-risk ALL, with the specific drugs and intensity adjusted based on how the child’s cancer responds and its genetic profile.
Genetic Factors That Affect the Outlook
Not all childhood leukemia behaves the same way. Certain genetic features in the cancer cells can make the disease more or less responsive to treatment. Children whose leukemia cells have favorable chromosomal patterns may have cure rates well above 90%, while high-risk genetic subtypes lower those odds significantly.
Among the higher-risk subtypes, children with Philadelphia chromosome-positive ALL have a five-year overall survival of about 70%. A related subtype called Philadelphia-like ALL has similar survival in young children (around 73%) but drops sharply in older adolescents and young adults. Children whose leukemia cells have fewer chromosomes than normal (hypodiploid ALL) have a five-year overall survival of roughly 61%. The rarest and most aggressive subtype, carrying a specific gene fusion called TCF3::HLF, has a five-year survival of only about 38%.
A child’s white blood cell count at diagnosis also matters. Counts above 100,000 per microliter at diagnosis predict a worse outcome, particularly in Philadelphia chromosome-positive cases. These risk factors help doctors decide how aggressively to treat and whether a bone marrow transplant should be considered.
What Happens If Leukemia Comes Back
Relapse occurs in roughly 10 to 20% of children treated for ALL. Survival after relapse is possible but significantly harder, with overall post-relapse survival around 50%. Timing matters enormously. Children who relapse late (well after finishing treatment) have a five-year overall survival of about 77%, while those who relapse very early during treatment have a five-year survival closer to 47%.
For children whose leukemia returns or doesn’t respond to standard chemotherapy, newer treatments are changing the outlook. CAR-T cell therapy, which reprograms a patient’s own immune cells to attack leukemia, has shown striking results. In a study of infants with relapsed or treatment-resistant ALL, 94% of treated patients achieved complete remission with no detectable residual disease. The one-year leukemia-free survival after CAR-T was 75%, and three-year survival was about 64%. These are children who had run out of conventional options.
Life During and After Treatment
Even with excellent cure rates, the treatment journey is physically and emotionally demanding. About 20% of children undergoing ALL treatment experience depression, and 19% experience anxiety. Roughly 12% show measurable physical impairment during therapy, and a similar percentage show emotional impairment. These difficulties tend to start early in treatment and can persist. Nearly three-quarters of children in treatment require some form of school-based support, most commonly special education accommodations.
The effects of treatment can extend well beyond the last dose of chemotherapy. Between 60% and 90% of childhood cancer survivors develop at least one chronic health condition over their lifetime, and by age 50, survivors have experienced an average of 17 chronic health conditions, nearly 5 of which are severe or life-threatening. Cardiovascular disease is the leading cause of premature death among long-term survivors after cancer recurrence and second cancers. Survivors also face an elevated risk of developing a new, unrelated cancer later in life, with a 30-year cumulative incidence of about 8% for malignant tumors (excluding skin cancers).
The good news is that these late effects have been decreasing as treatment protocols evolve. The 20-year incidence of heart failure for patients treated in the 1990s dropped to just 0.54%, reflecting lower doses of the drugs most linked to heart damage. Children treated with chemotherapy alone, rather than radiation, generally avoid the worst growth and hormonal complications. Survivors of childhood ALL treated without radiation do not appear to have higher obesity rates than the general population, though some may end up shorter than expected as adults.
The 20-year all-cause late mortality rate for childhood ALL survivors diagnosed between 1970 and 1999 was 6.6%. For children diagnosed and treated with modern protocols, that number is expected to be lower. Long-term follow-up care, typically through a survivorship clinic, helps catch and manage these late effects early.